We’ve been selected to pitch at HTGF MedTech Pitch Day 2026, one of Europe’s most competitive investor events for medical technology startups. From approximately 100 applications across 14 countries, we’re among the companies chosen to present VIOSync to leading MedTech investors and corporate decision-makers on March 17th in Freiburg, Germany.
About HTGF MedTech Pitch Day
The MedTech Pitch Day is organized by High-Tech Gründerfonds (HTGF), B. Braun Innovation Hub, B. Braun Stiftung, and Dräger, bringing together the German and European MedTech investment ecosystem in a single-day event focused exclusively on healthcare technology innovation.
Selected startups receive 10 minutes to pitch their technology, followed by Q&A with an audience that includes:
- Seed and Series A investors specializing in MedTech and HealthTech
- Corporate venture arms from leading medical device companies
- Strategic partnership teams from B. Braun, Dräger, and other major MedTech players
- Business development executives evaluating acquisition and licensing opportunities
- Industry advisors and ecosystem connectors across the European healthcare landscape
This isn’t a pitch competition where one company wins. It’s a curated platform designed to facilitate meaningful connections between selected startups and the investors and corporates who can actually fund or partner with them.
About High-Tech Gründerfonds (HTGF)
HTGF is one of the most active early-stage investors in Germany and Europe, with a particular focus on Deep Tech and Life Sciences companies. Since its founding in 2005, HTGF has:
- Financed approximately 800 startups
- Achieved 200 successful exits
- Managed over €2 billion in fund volume
- Operated as a Public-Private Partnership backed by the German Federal Ministry for Economic Affairs and Energy, KfW Capital, and 45 corporate and family office investors
HTGF invests in pre-seed and seed stages, with the capability to participate significantly in follow-on rounds. Their investment team brings founder experience, scaling expertise, and deep technical knowledge across multiple sectors, making them one of the most credible early-stage investors for companies building complex, regulated technologies.
The Selection Process
Applications opened in January 2026 with a deadline of February 22nd. Approximately 100 companies from 14 countries submitted non-confidential pitch decks, which were screened by a jury of investors and industry experts.
Selected companies represent a range of MedTech and HealthTech innovations, from AI-powered diagnostics and digital therapeutics to medical devices and regulatory technology. The common thread: technologies addressing real unmet clinical needs with credible pathways to market.
For Aisthesis Medical, being selected validates that VIOSync, with its focus on earlier sepsis detection through Explainable AI and Digital Patient Twins, represents the kind of innovation HTGF’s ecosystem is actively looking to support and scale.
Why This Matters for VIOSync
Pitching at HTGF MedTech Pitch Day creates three distinct opportunities:
1. Investor Access
We’re currently closing our £2.7M seed round. The investors attending MedTech Pitch Day include exactly the funds that lead Series A rounds in clinical AI and medical devices, providing visibility to the capital partners we’ll need for commercial deployment and European market expansion over the next 18-24 months.
2. Corporate Partnership Potential
B. Braun and Dräger aren’t just event sponsors, they’re global leaders in hospital equipment and acute care technology. B. Braun operates in over 60 countries with products used in ICUs worldwide. Dräger specializes in patient monitoring and acute care systems. Both companies have strategic interest in AI-powered clinical decision support that integrates with their existing infrastructure.
For VIOSync, which is designed to integrate directly into hospital workflows and leverage data from patient monitoring systems, partnerships with companies like B. Braun and Dräger could accelerate deployment by embedding sepsis detection capabilities into hardware platforms already trusted by clinicians.
3. European Market Credibility
While Aisthesis Medical is UK-based, the European market, particularly Germany, represents significant commercial opportunity for clinical AI platforms. Germany has some of Europe’s most advanced hospital systems, strong adoption of digital health technologies, and regulatory frameworks (CE MDR, EU AI Act) that we’re already building to comply with.
Being selected for HTGF MedTech Pitch Day signals to the German and broader European healthcare ecosystem that VIOSync is being taken seriously by the investors and corporates who shape MedTech adoption across the region.
What We’ll Be Pitching: VIOSync for Earlier Sepsis Detection
VIOSync is designed to support clinicians in recognizing sepsis and acute deterioration earlier through:
- Predictive Intelligence: Retrospective studies suggest the potential for sepsis risk prediction up to 48 hours in advance, depending on setting and data availability
- Explainable AI (XAI): Transparent outputs designed to support clinician trust, validation, and regulatory auditability
- Workflow Integration: Evidence-based guidance embedded directly into clinical workflows, reducing friction at the bedside
- Digital Patient Twin Architecture: Multimodal data fusion integrating vital signs, lab results, and clinical context
The platform is currently completing CE MDR technical documentation with retrospective validation studies demonstrating clinical potential. We’re building VIOSync to be predictive (not reactive), explainable (not black-box), integrated (not another standalone dashboard), and evidence-ready (not pilot-forever).
Sepsis remains one of the leading causes of preventable hospital deaths globally. The clinical challenge isn’t recognizing obvious sepsis, it’s detecting deterioration early enough to intervene before organ dysfunction becomes irreversible. That’s the problem VIOSync is designed to solve.
The German MedTech Ecosystem: Why It Matters
Germany is Europe’s largest MedTech market and a global leader in medical device manufacturing. Companies like B. Braun, Dräger, Siemens Healthineers, and Fresenius are headquartered there, creating an ecosystem where:
- Hospital systems have budget and infrastructure for digital health adoption
- Regulatory pathways (CE MDR, EU AI Act) are well-understood and actively navigated
- Corporate partnerships with global MedTech leaders can accelerate international scaling
- Investors understand the complexities of healthcare technology commercialization
For UK-based companies like Aisthesis Medical, Germany represents both a significant market opportunity and a strategic gateway to broader European adoption. Success in Germany often validates technologies for deployment across other EU markets.
Looking Ahead: March 17th in Freiburg
The event runs from 10:00 to 18:00 on March 17th, with pitches, networking sessions, and one-on-one meetings between startups and investors. All sessions are conducted in English.
For Aisthesis Medical, this is an opportunity to present VIOSync to the investors and corporates who can support our next phase of growth, from seed funding and Series A preparation to strategic partnerships that accelerate European market entry.
We’ll be sharing updates from Freiburg as we connect with the European MedTech ecosystem on March 17th.
About Aisthesis Medical
Aisthesis Medical is a deep-tech medtech startup developing cutting-edge AI-driven solutions to revolutionize acute care. Founded in 2022, our mission is to save lives by predicting and preventing sepsis before it becomes fatal. Aisthesis Medical is revolutionizing acute care with VIOSync, the first holistic AI-driven digital patient twin platform that goes beyond early sepsis prediction to guide clinical intervention and optimize patient outcomes. VIOSync, predicts sepsis up to 48 hours earlier, integrates directly into hospital workflows, and optimizes treatment pathways to reduce unnecessary antibiotic use.
Ready to Learn More?
If you’re a hospital, NHS trust, or healthcare investor interested in learning more about VIOSync or our security and compliance posture, we’d love to connect.
📩 Get in touch: https://aisthesismed.com/contact/
🌐 Learn more about VIOSync: https://aisthesismed.com/product/